Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zaltenibart - Omeros Corporation

Next Previous
Search
Drug Profile

Zaltenibart - Omeros Corporation

Alternative Names: OMS-906

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helion Biotech; Medical Research Council; University of Leicester
  • Developer Omeros Corporation
  • Class Anti-inflammatories; Monoclonal antibodies; Urologics
  • Mechanism of Action Mannose-binding protein-associated serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Paroxysmal nocturnal haemoglobinuria
  • Phase II Glomerulonephritis
  • No development reported Arthritis

Most Recent Events

  • 31 Mar 2025 Phase-III clinical trials in Paroxysmal nocturnal haemoglobinuria (Parenteral)
  • 21 Mar 2025 Omeros Corporation announces intention to submit BLA for zaltenibart in paroxysmal nocturnal hemoglobinuria by Q4 2026
  • 16 Dec 2024 Efficacy and adverse events data from a phase II trial in Paroxysmal nocturnal hemoglobinuria released by Omeros Corporation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top